Summary of COVID-19 brensocatib studies
Studies
Meta Analysis
Hide extended summaries
404 patient brensocatib late treatment RCT: 41% higher mortality (p=0.02) and 39% worse 7-point scale results (p=0.007).
RCT 406 hospitalized COVID-19 patients in the UK showing higher mortality and worse clinical status with brensocatib (DPP-1 inhibitor) vs. placebo. Although blood neutrophil elastase activity was reduced, indicating the desired pharmacological effect, the results show worse clinical outcomes. Authors hypothesize that inhibiting DPP-1 and neutrophil serine proteases may have negatively impacted the delicate balance of neutrophils' protective and deleterious effects in the immune response to SARS-CoV-2.
Dec 2022, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260022002612, https://c19p.org/keir
404 patient brensocatib late treatment RCT: 41% higher mortality (p=0.02) and 39% worse 7-point scale results (p=0.007).
RCT 406 hospitalized COVID-19 patients in the UK showing higher mortality and worse clinical status with brensocatib (DPP-1 inhibitor) vs. placebo. Although blood neutrophil elastase activity was reduced, indicating the desired pharmacological effect, the results show worse clinical outcomes. Authors hypothesize that inhibiting DPP-1 and neutrophil serine proteases may have negatively impacted the delicate balance of neutrophils' protective and deleterious effects in the immune response to SARS-CoV-2.
Dec 2022, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260022002612, https://c19p.org/keir
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.